T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

Recruiting

Phase 1

attIL2-TILT Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT06474676

Conditions

Metastatic Soft-tissue Sarcoma

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Cyclophosphamide

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-10. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2025-10-03.